Gilead taps Durham gene editing firm for $445M deal
California biotech Gilead Sciences (Nasdaq: GILD) has teamed up with a Durham-based Precision BioSciences to develop therapies targeting hepatitis B – a deal that could be worth $445 million.
At the center of the deal is Durham-based Precision BioSciences’ genome editing platform, dubbed ARCUS.
On an earnings call, John McHutchison, Gilead’s chief scientific officer and head of research and development (and former Associate Director of t he Duke Clinical Research Institute in Durham), said…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Lauren K. Ohnesorge Source Type: news